We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.65 | -0.86% | 75.11 | 75.00 | 76.00 | 76.47 | 75.92 | 76.43 | 6,663,140 | 01:00:00 |
From May 2021 to May 2024
By Kyle Morris
AstraZeneca PLC said Friday that it has signed an exclusive global collaboration and license agreement with Neurimmune for the development and commercialization of NI006, a treatment for transthyretin amyloid cardiomyopathy.
The pharmaceutical giant said its rare disease group Alexion will pay Neurimmune an upfront payment of $30 million, with the potential for additional milestone payments of up to $730 million based on development, regulatory and commercial milestones. In addition, further low-to-mid teen royalties will be paid on net sales of any approved medicine resulting from the agreement.
Under the deal, Alexion will be granted an exclusive worldwide license to develop, manufacture and commercialize NI006.
NI006 is designed to treat transthyretin amyloid cardiomyopathy by enabling the removal of amyloid fibril deposits in the heart, with the potential to treat patients with advanced stages of the condition.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 07, 2022 02:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
